Q-omics provides the consensus-scored SYT14P1 profile across patient tissues and cancer cell-line models. SYT14P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, SYT14P1 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, SYT14P1 RNA expression shows 7,278 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ESCA, and LUSC as cancer lineages where SYT14P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT14P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT14P1 survival associations across molecular data types. SYT14P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT14P1 RNA expression–survival associations across cancer types. High SYT14P1 expression shows unfavorable associations in LUAD, COAD and KIRC, but favorable associations in ESCA, HNSC and LUSC. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify ESCA as the clearest survival context for SYT14P1 RNA expression.
This table summarizes SYT14P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SYT14P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT14P1 shows lower tumor expression in HNSC and higher tumor expression in LUSC, THCA and CHOL. The LUSC box plot shows higher SYT14P1 RNA expression in tumor versus normal tissue (log2 FC = +0.101, t-test p = .001).
This table shows molecular features associated with SYT14P1 in patient tissues and cancer cell lines. In patient samples, SYT14P1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
